Established in 1950, Taro Pharmaceutical Industries Ltd. is a multinational science-based pharmaceutical company that develops, manufactures and markets generic and branded prescription and over-the-counter (OTC) pharmaceutical products. Taro¡¦s research programs and niche strategy have enabled the Company to achieve leadership in dermatological products in the United States. Business Overview Taro develops, manufactures and markets prescription and OTC pharmaceutical products primarily in the United States, Canada and Israel. Taro¡¦s primary areas of focus include pediatric creams and ointments, liquids, capsules and tablets, mainly for the dermatological, topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. |
¤¤°ê¯««ÂÃÄ·~¶°¹Î¦³¤½¥q¬O¤¤°ê³Ì¤jªº²{¥N¤¤ÃĪ`®g²G¤Î³n½¦Ån»s³y°Ó¡C ¶°¹Î©ó»´äÁp¦X¥æ©ö©Ò¥DªO¤W¥«¡A¬°ùڥͺî¦X«ü¼Æ¦¨¥÷ªÑ¡A¨Ã³Q¿ï¬°ºÖ¥¬´µ¨È¬w200³Ì¨Î¤¤¤p¥ø·~¤§¤@¡C ¯««ÂÃÄ·~ªº²£«~¥Dn¤À¬°¤¤ÃĪ`®g²G¡B¤¤Ãijn½¦Ån¤Î¤¤ÃÄÁû²É¤T¤jÃþ¡A´£¨Ñ°w¹ï¤¤¦Ñ¦~¤H¡B§Ü¯f¬r¤Î¨àµ£¥ÎÃijo¤T¤j¼ç¤OÀu«p¤§¥«³õ¡C¥»¶°¹Îªº²£«~¤@ª½¥H¨ä¥Dn«~µP¡u¯««Â¡v¾P°â¡A¬°¡u¤¤°ê¹£¦W°Ó¼Ð¡v¡C |
ÂåÃĪÑ.... Chugai Pharmaceutical ¤¤¥~»sÃÄ ( ¤éªÑ 4519 , ¬üªÑ CHGCY ) http://mikeon88.freebbs.tw/viewthread.php?tid=44729&extra=page%3D1 |
¤éªÑ..»sÃÄ..Shionogi 塩³¥¸q»s薬®è¦¡会ªÀ(¤éªÑ 4507,¬üªÑ SGIOY,SGIOF) http://mikeon88.freebbs.tw/viewthread.php?tid=44885&page=1&extra=page%3D1#pid100162 |
Sumitomo Dainippon Pharma Co., Ltd. | |
¤j¤é¥»¦í¤Í»s薬®è¦¡会ªÀ | |
®è¦¡·|ªÀ | |
¤j¤é¥»»sÃÄ1897¦~5¤ë14¤é ¦í¤Í»sÃÄ1984¦~2¤ë6¤é ¦X¨Ö2005¦~10¤ë1¤é | |
¥Nªí¨ú½l§Ð·|ªø®cªZ°·¦¸¦ ¥Nªí¨ú½l§ÐªÀªø¦h¥Ð¥¿¥@ | |
¤j¨Á©²¤j¨Á¥«¤¤¥¡°Ï¹D×Ëm¤G¤B¥Ø6µf8¸¹ | |
Âå薬«~¡BÁ{§ÉÀË査ÃÄ¡BÂåÀø¾÷¾¹¡B°Êª«¥ÎÂå薬«~ ¹«~²K¥[ª«¡B¤u·~薬«~¡B¨ä¥L¤Æ¾Ç»s«~ªº»s³y | |
3,0637.00»õ¤é¶ê¡]2010¦~¡A¥þÅéÀ禬¡^ | |
7,407¦W¡]2010¦~3¤ë31¤é²{¦b¡^ | |
224»õ円¡]2009¦~3¤ë¥½²{¦b¡^ | |
¨C¦~3¤ë31¤é | |
¦í¤Í¤Æ¾Ç50.12% 稲畑産·~6.86% ¡]2010¦~3¤ë31¤é²{¦b¡^ | |
DSP¤¨óÇÑÆãÇÅ¡®ÇÇÛǧÇç®è¦¡·|ªÀ | |
http://www.ds-pharma.co.jp/ |
¦ì©ó¤j¨Á©²¤j¨Á¥«¤¤¥¡°Ï¤j¤é¥»¦í¤Í»sÃÄÁ`³¡¡C
[url=https://zh.wikipedia.org/wiki/Fileogo_of_Eisai.png][/url] | |
ǤÆãDzÇ~®è¦¡会ªÀ | |
¤W¥«¤½¥q | |
ªFÃÒ1³¡¡G4523 TOPIX 100«ü¼Æ ¤é¸g225«ü¼Æ | |
(1941¦~12¤ë6¤é¡A76¦~«e) | |
Toyoji Naito | |
¤ºÃô¸¤Ò (Á`µôÝ¥ôCEO) | |
112-8088 ¤é¥»ªF¨Ê¤å¨Ê°Ï¤p¥Û¤t 4-6-10 | |
»sÃĤ½¥q | |
¡¶ US$ 5.82 billion (°]¬F¦~«× 2013) (¤é¤¸ 600.4 billion) (FY 2013) | |
¡¶ US$ 320 million (FY 2013) (JPY 33 billion) (FY 2013) | |
10,419 (consolidated, as of March 31, 2014) | |
©x¤èºô¯¸ | |
[1] |
Public KK | |
TYO: 4151 FWB: KY4 Nikkei 225 Component | |
July 1, 1949 | |
Ohtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100-8185, Japan | |
Nobuo Hanai, (CEO and President) | |
$ 3.548 billion USD (FY 2013) (¥ 340.61 billion JPY) (FY 2013) | |
$ 31.32 million USD (FY 2013) (¥ 30.07 billion JPY) (FY 2013) | |
7,532 (consolidated) (as of December 31, 2017) | |
Kirin Holdings Company, Limited | |
47 (33 in Japan and 14 overseas countries) | |
Official website | |
Footnotes / references [1][2][3] |
Sumitomo Dainippon Pharma Co., Ltd. | |
[/url] | |
¤j¤é¥»¦í¤Í»s薬®è¦¡会ªÀ | |
®è¦¡·|ªÀ | |
¤j¤é¥»»sÃÄ1897¦~5¤ë14¤é ¦í¤Í»sÃÄ1984¦~2¤ë6¤é ¦X¨Ö2005¦~10¤ë1¤é | |
¥Nªí¨ú½l§Ð·|ªø®cªZ°·¦¸¦ ¥Nªí¨ú½l§ÐªÀªø¦h¥Ð¥¿¥@ | |
¤j¨Á©²¤j¨Á¥«¤¤¥¡°Ï¹D×Ëm¤G¤B¥Ø6µf8¸¹ | |
Âå薬«~¡BÁ{§ÉÀË査ÃÄ¡BÂåÀø¾÷¾¹¡B°Êª«¥ÎÂå薬«~ ¹«~²K¥[ª«¡B¤u·~薬«~¡B¨ä¥L¤Æ¾Ç»s«~ªº»s³y | |
3,0637.00»õ¤é¶ê¡]2010¦~¡A¥þÅéÀ禬¡^ | |
7,407¦W¡]2010¦~3¤ë31¤é²{¦b¡^ | |
224»õ円¡]2009¦~3¤ë¥½²{¦b¡^ | |
¨C¦~3¤ë31¤é | |
¦í¤Í¤Æ¾Ç50.12% 稲畑産·~6.86% ¡]2010¦~3¤ë31¤é²{¦b¡^ | |
DSP¤¨óÇÑÆãÇÅ¡®ÇÇÛǧÇç®è¦¡·|ªÀ | |
http://www.ds-pharma.co.jp/ |
Hisamitsu Pharmaceutical Co., Inc. | |
¤W¥«¤½¥q ªFÃÒ1³¡¡G4530 ¦WÃÒ1³¡¡G4530 | |
1847¦~ | |
¤¤冨³Õ¶©¡]¦æ¬FÁ`µô¤ÎªÀªø¡^ | |
¤é¥»¦õ¶P¿¤³¾Ñᥫ¥Ð¥N¤j©xËm408 | |
»sÃÄ¡BÂåÀø½Ã¥Í | |
¡¶1,240»õ¤é¶ê¡]2009¦~2¤ë¡^ | |
1,428¤H¡]2012¦~2¤ë¡^ | |
Hisamitsu America Inc. Noven Pharmaceuticals, Inc. Hisamitsu Farmaceutica do Brasil Ltda. ¤[¥ú»sÃħ޳N¿Ô¸ß¡]¥_¨Ê¡^¦³¤½¥q Hisamitsu Vietnam Pharmaceutical Co., Ltd. PT.Hisamitsu Pharma Indonesia Hisamitsu UK Limited | |
www.hisamitsu.co.jp |
Public KK | |
TYO: 4568 TOPIX Large 70 Component TOPIX 100 Component Nikkei 225 Component | |
Pharmaceutical | |
| |
Tokyo, Japan (2005) (by merger) | |
Daiichi Sankyo Building A/B 3-5-1, Nihonbashi-honcho, Chūō-ku, Tokyo 103-8426, Japan | |
Joji Nakayama, (CEO and President) | |
| |
$ 12.006 billion USD (FY2012) (¥ 997.852 billion JPY) (FY 2012) | |
$ 0.801 billion USD (FY2012) (¥ 66.621 billion JPY) (FY 2012) | |
32,229 (as of December 2013) | |
http://www.daiichisankyo.com | |
Footnotes / references [1][2] |
(Xetra¨t²Î¥æ©öªº)¤½²³¤½¥q | |
FWB: BAYN | |
1863¦~8¤ë1¤é¡A¥Ñ´I¾¤¼w¨½§Æ¡E«ô¦Õ¡]Friedrich Bayer¡^»P¬ù¿«¡E´I¾¤¼w¨½§Æ¡E«Â´µ¦Ò¯S¡]Johann Friedrich Weskott¡^«Ø¥ß | |
Werner Wenning (CEO) Manfred Schneider (ºÊ²z·|¥D®u) | |
¼w°ê°Ç¨U®w´Ë | |
»sÃÄ¡B¹A·~¡B¥Íª«§Þ³N¡B¤Æ¾Ç¤u·~ | |
°£¯ó¾¯¡B¹AÃÄ¡B½\ª«ºØ¤l¡BÂåÀøÃÄ«~ | |
¡¶ £á463.24»õ¡]2015¡^[1] | |
¡¶ £á62.50»õ¡]2015¡^[1] | |
¡¶ £á41.10»õ¡]2015¡^[1] | |
¡¶ £á739.17»õ¡]2015¡^[2] | |
¡¶ £á254.45»õ¡]2015¦~¦~¥½¡^[2] | |
116,800 (FTE, 2015)[1] | |
http://www.bayer.com/ |
Beiersdorf AG | |
ªÑ¥÷¤½¥q | |
FWB: BEI | |
1882¦~3¤ë28¤é | |
¦«°¨´µ-¥»¼w¡P¦j´µ (°õ¦æªø) | |
¼w°êº~³ù | |
¤Æ¤u¡BÂåÃÄ | |
Ó¤HÅ@²z²£«~ | |
£á 60.4 »õ¼Ú¤¸ (2012)[1] | |
£á 735 ¦Ê¸U (2012)[1] | |
£á 477 ¦Ê¸U (2012 ¦~¥½)[1] | |
£á 55.75 »õ (2012 ¦~¥½)[1] | |
£á 32.87 »õ (2012 ¦~¥½)[1] | |
16,605 (2012 ¦~¥½)[1] | |
Beiersdorf.com |
Fresenius SE & Co. KGaA | |
¼Ú¬wªÑ¥÷¤½¥q¤Î¨â¦X¤½¥q¡]FWB: FRE¡^ | |
1912¦~ | |
·R¼wµØ¡P¶O´Ë¤×´µ ¡]Eduard Fresenius¡^ | |
¯Qº¸¤Ò¡P°¨§J¡P´µ©`¼w¡]CEO¡^ ¡]Ulf Mark Schneider¡^ | |
¼w°ê¤Ú¯S¬x³ù | |
ÂåÀø§Þ³N | |
³zªR¡BÀR¯ßª`®g¡BÃĪ«ªvÀø¡B Âå°| | |
£á159.7»õ¡]2010¦~¡^[1] | |
£á24.18»õ ¡]2010¦~¡^[1] | |
£á6.22»õ ¡]2010¦~¡^[1] | |
£á235.8»õ¡]2010¦~¡^[1] | |
137550 ¡]2010¦~¡^[1] | |
www.fresenius.se |
¤W¥«¤½¥q ¼w°êµù¥U (FWB: MRK) |
1668¦~ |
¥±¨½¼w¨½§Æ ¶®¦U Àq§J |
¥dº¸-§J¹p (CEO¤Î¸³¨Æ§½¥D®u), «Â·G ¿ü©i´Ë (²z¨Æ·|¥D®u) |
¼w°ê¹F©i¬I¶ð¯S |
¤Æ¤u, »sÃÄ |
²G´¹, ¥Í©R¬ì¾Ç¤Î¤Æ¾Ç©Ê¯à, «D³B¤èÃÄ, ¤p¥÷¤l¤Î ¥Íª«»sÃÄ |
£á9.291 billion (2010)[1] |
£á1.113 billion (2010)[1] |
£á632.1 million (2010)[1] |
£á22.39 billion (end 2010)[1] |
£á10.37 billion (end 2010)[1] |
38000 (end 2012)[1] |
www.merck-china.com |
Current Merck logo, introduced in 2015. | |
Publicly traded KGaA | |
FWB: MRK | |
Chemicals pharmaceuticals | |
1668; 350 years ago | |
Friedrich Jacob Merck | |
Darmstadt, Germany | |
Worldwide | |
Stefan Oschmann (CEO and Chairman of the executive board), Wolfgang Büchele (Chairman of the supervisory board) | |
Liquid crystals, life science and performance chemicals, over-the-counter medicines, small molecules and biopharmaceuticals | |
£á15.024 billion (2016)[1] | |
£á1.629 billion (2016)[1] | |
$42.13 billion (2016)[2] | |
Ca. 50,000 (2016)[3] | |
E. Merck KG (70.3% of capital)[4][5][6] | |
www.merckgroup.com |
Public limited company | |
LSE: AZN Nasdaq Stockholm: AZN FTSE 100 Component | |
Pharmaceutical Biotechnology | |
Astra AB Zeneca Group plc | |
6 April 1999; 19 years ago | |
Cambridge, England[1] | |
Global | |
Leif Johansson(Chairman) Pascal Soriot (CEO) | |
Pharmaceutical products | |
US$22.465 billion (2017)[2] | |
US$3.677 billion (2017)[2] | |
US$2.868 billion (2017)[2] | |
59,700 (2017)[3] | |
MedImmune | |
www.astrazeneca.com |
¤½¦@¦³¤½¥q | |
LSE¡GAZN OMX: AZN NYSE¡GAZN | |
Astra AB Zeneca Group plc | |
1999¦~4¤ë6¤é | |
Leif Johansson ¡]¸³¨Æªø¡^ Pascal Soriot ¡]CEO¡^ | |
^°êÛ´° | |
¥þ²y | |
»sÃÄ¡B¥Íª«§Þ³N | |
ÃĪ« | |
US$260.95»õ¡]2014¡^[1] | |
US$21.37»õ¡]2014¡^[1] | |
US$12.35»õ¡]2014¡^[1] | |
50,000¡]2014¡^[2] | |
MedImmune | |
www.astrazeneca.com |
Åwªï¥úÁ{ ¤Úµá¯S¯Z ¬x·ç®õ (Michael On) (http://mikeon88.freebbs.tw/) | Powered by Discuz! 5.0.0 |